BOLT — Bolt Biotherapeutics Balance Sheet
0.000.00%
- $13.55m
- -$33.77m
- $7.69m
- 22
- 57
- 14
- 21
Annual balance sheet for Bolt Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 22.8 | 186 | 169 | 102 | 47.3 |
Net Total Receivables | — | — | — | — | 1.17 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25.4 | 189 | 173 | 106 | 50.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 16.4 | 30.6 | 28.5 | 24.1 | 24.9 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 46.5 | 308 | 228 | 160 | 99.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.3 | 21.3 | 23.1 | 20.5 | 15.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 46.2 | 57.6 | 56.3 | 47 | 42.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 0.349 | 250 | 172 | 113 | 57.2 |
Total Liabilities & Shareholders' Equity | 46.5 | 308 | 228 | 160 | 99.6 |
Total Common Shares Outstanding |